Collplant Biotechnologies Ltd (CLGN) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Collplant Biotechnologies Ltd stock (CLGN) is currently trading at $0.71. Collplant Biotechnologies Ltd PS ratio (Price-to-Sales) is 3.18. Analyst consensus price target for CLGN is $11.12. WallStSmart rates CLGN as Sell.
- CLGN PE ratio analysis and historical PE chart
- CLGN PS ratio (Price-to-Sales) history and trend
- CLGN intrinsic value — DCF, Graham Number, EPV models
- CLGN stock price prediction 2025 2026 2027 2028 2029 2030
- CLGN fair value vs current price
- CLGN insider transactions and insider buying
- Is CLGN undervalued or overvalued?
- Collplant Biotechnologies Ltd financial analysis — revenue, earnings, cash flow
- CLGN Piotroski F-Score and Altman Z-Score
- CLGN analyst price target and Smart Rating
Collplant Biotechnologies
📊 No data available
Try selecting a different time range
Smart Analysis
Collplant Biotechnologies Ltd (CLGN) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book, revenue growth. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Collplant Biotechnologies Ltd (CLGN) Key Strengths (2)
Trading below book value, meaning the market prices it less than net assets
Revenue surging 1825.00% year-over-year
Supporting Valuation Data
Collplant Biotechnologies Ltd (CLGN) Areas to Watch (5)
Company is destroying shareholder value
Losing money on operations
Very low institutional interest at 12.23%
Micro-cap company with very limited liquidity and high volatility
Revenue is fairly priced at 3.18x sales
Supporting Valuation Data
Collplant Biotechnologies Ltd (CLGN) Detailed Analysis Report
Overall Assessment
This company scores 34/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 2 register as strengths (avg 10.0/10) while 5 fall into concern territory (avg 2.2/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book, Revenue Growth. Valuation metrics including Price/Book (0.80) suggest the stock is attractively priced. Growth metrics are encouraging with Revenue Growth at 1825.00%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Institutional Own.. Some valuation metrics including Price/Sales (3.18) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -92.70%, Operating Margin at -4555.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -92.70% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 1825.00% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
CLGN Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
CLGN's Price-to-Sales ratio of 3.18x trades at a deep discount to its historical average of 73.96x (5th percentile). The current valuation is 99% below its historical high of 556.22x set in Jan 2023, and 13% above its historical low of 2.82x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~63.4x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Collplant Biotechnologies Ltd (CLGN) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Collplant Biotechnologies Ltd is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 2M with 1825% growth year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Revenue growing at 1825% YoY, reaching 2M. This pace significantly outperforms most BIOTECHNOLOGY peers.
Spending 84% of revenue (2M) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -3M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Collplant Biotechnologies Ltd maintain 1825%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Collplant Biotechnologies Ltd.
Bottom Line
Collplant Biotechnologies Ltd is a high-conviction growth story with revenue accelerating at 1825% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin 0.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Collplant Biotechnologies Ltd(CLGN)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
CollPlant Biotechnologies Ltd., an aesthetic and regenerative medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. The company is headquartered in Rehovot, Israel.